Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Posiphen in Early Alzheimer's Disease
NCT02925650Phase 2Completed
- Sponsor
- Annovis Bio, Inc.
- Start
- Mar 2017
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of buntanetap in Alzheimer's disease (AD) (4 arms), sponsored by Annovis Bio, Inc. Primary endpoints: Safety and Tolerability of Multiple Ascending Doses of Posiphen: Reports of Adverse Events or Study Discontinuations up to 25 days, The Levels of Posiphen and Its Metabolites Will be Determined in Plasma and 2 more. Started Mar 2017; status: completed.
02
Drugs
buntanetap
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02925650.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02925650.